Herceptin Increases event-free survival in locally advanced HER2-postive breast cancer

Share :
Published: 11 Mar 2009
Views: 14997
Dr Luca Gianni - Director of Medical Oncology, National Cancer Institute, Milan
Among patients with HER2-positive, locally advanced breast cancer, neoadjuvant treatment with Herceptin increased three-year, event-free survival to 70 percent compared with 53 percent among those receiving chemotherapy alone. The addition of trastuzumab (Herceptin) was well tolerated with acceptable cardiac safety. Researchers claim this phase III clinical trial establishes chemotherapy with one year of Herceptin as a standard treatment option in this patient population. Speaking at the 2008 San Antonio Breast Cancer Symposium.